NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Fractyl Health, Inc. (GUTS) Stock Analysis

Fractyl Health, Inc. (GUTS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GUTS

$1.15

−$0.18 (−13.53%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GUTS with… →

GUTS Key Statistics

As of Oct 21, 2026
Trading
Open
$1.36
Previous Close
$1.33
Day's Range
1.12–1.37
52-Week Range
1.12–29.34
Volume
982.33K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.42
Valuation
Market Cap
$15.25M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−10.56
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$140.95M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
13.26M
1-Year Return
−14.18%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
399.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GUTS closed at $1.15, −14.18% over 1 year.

Fractyl Health, Inc. (GUTS) has a market capitalization of $15.25M.

In fiscal 2025, GUTS reported revenue of $0.00.

GUTS Stock Return by Calendar Year

Fractyl Health, Inc. (GUTS) return since Feb 2024: what $10,000 became

1 year
$10,000 $8,582
−14.18%
Since Feb 2024
$10,000 $895
−91.05%

If you had invested $10,000 in Fractyl Health, Inc. (GUTS) at the close on February 2, 2024, the earliest close on record here, it would have been worth $895 at the close on October 21, 2026: −91.05% in total, −58.88% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−47.73%
2025+6.80%
2024 (partial year)−83.97%

As of October 21, 2026.

GUTS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$140.95M—
2024$93.00K−$68.69M−73,864.5%
2023$120.00K−$77.09M−64,242.5%
2022$0.00−$46.45M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$96.82M−$140.95M—
2024$93.00K$43.00K−$93.53M−$68.69M−73,864.5%
2023$120.00K$43.00K−$50.84M−$77.09M−64,242.5%
2022$0.00$0.00−$49.39M−$46.45M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Fractyl Health, Inc. (GUTS) at $15.25M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 100 employees.

Over the past 52 weeks the price has ranged from $1.12 to $29.34. The most recent close on file for GUTS is $1.15, dated October 21, 2026. That is −$0.18 (−13.53%) against the previous close. The latest close sits 2.68% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. That is −100.00% against the prior fiscal year, when revenue was $93.00K. The same year closed with a net loss of $140.95M. Trailing earnings per share are −10.56.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −14.18%. The stored price history starts on February 2, 2024, and the total return since then is −91.05%. The reported beta is 2.42. Daily returns over the trailing 2 years annualize to a volatility of 735.51%.

Growth & Income

The record shows no dividend for GUTS.

The record holds one complete calendar year, 2025, which returned +6.80%. 2026 is still running; the total return is −47.73% year to date.

Peer Comparison

Fractyl Health, Inc. (GUTS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fractyl Health, Inc. GUTS $15.25M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Fractyl Health, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Fractyl Health, Inc.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Visit website →